WO1996002238A1 - Agent neurotrope et sedatif et son procede d'obtention - Google Patents

Agent neurotrope et sedatif et son procede d'obtention Download PDF

Info

Publication number
WO1996002238A1
WO1996002238A1 PCT/RU1995/000155 RU9500155W WO9602238A1 WO 1996002238 A1 WO1996002238 A1 WO 1996002238A1 RU 9500155 W RU9500155 W RU 9500155W WO 9602238 A1 WO9602238 A1 WO 9602238A1
Authority
WO
WIPO (PCT)
Prior art keywords
stearic acid
methyl cellulose
white
neurotropic
talc
Prior art date
Application number
PCT/RU1995/000155
Other languages
English (en)
Russian (ru)
Inventor
Leonid Dmitrievich Smirnov
Tatyana Alexandrovna Voronina
Kirill Mikhailovich Djumaev
Jury Valentinovich Burov
Original Assignee
Aktsionernoe Obschestvo Zakrytogo Tipa 'olvik'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktsionernoe Obschestvo Zakrytogo Tipa 'olvik' filed Critical Aktsionernoe Obschestvo Zakrytogo Tipa 'olvik'
Publication of WO1996002238A1 publication Critical patent/WO1996002238A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the invention is related to the field of medicine, in particular, to the non-injurious and the invasive system and the method of its delivery.
  • a well-known and tranquilizing medication is mexidol (see, for example, ⁇ .D. ⁇ .
  • ⁇ me ⁇ g ⁇ , ⁇ i is ⁇ l- z ⁇ vanii me ⁇ sid ⁇ la as ine ⁇ tsy ⁇ i ⁇ u ⁇ s ⁇ v ⁇ y ⁇ e ⁇ a ⁇ ii (b ⁇ lee 30 days) nablyudae ⁇ sya change s ⁇ e ⁇ a ⁇ a ⁇ ma ⁇ - l ⁇ giches ⁇ y a ⁇ ivn ⁇ s ⁇ i ⁇ e ⁇ a ⁇ a ⁇ a, ch ⁇ vy ⁇ azhae ⁇ sya ⁇ ⁇ vy- shenii ag ⁇ essivn ⁇ s ⁇ i, em ⁇ tsi ⁇ naln ⁇ y ⁇ ea ⁇ ivn ⁇ s ⁇ i, The decrease
  • 35 changes, in particular, white clay, quick-drying starch, stearic acid calcium, stearic acid, talc, ⁇ 96/02238 ⁇ 95 / 00155
  • 25th in the wall is 1.5 mm
  • Table I shows the results of the analysis of 0.125 g test samples, commercial samples
  • Table 2 shows the results of the analysis of the release of methoxide from a single tablet.
  • the process was simulated on the basis of the Jouvet method. Livestock placed in extreme conditions, ⁇ . e. on small areas in the pool with water for 24 hours, which caused a disruption of the acute phase of sleep, limited mobility, and the isolation of civil and physical stress. A particular feature of the Jouveau process is the absence of the possibility of avoiding the complex of occupational impacts.
  • the effect of the antioxidant effect is at a high level during the whole course of the use of the drug, when the drug is not injected, the drug is not in use.
  • Table 3 shows the data on the impact of the index after the process on the basis of the statistics of research and development activities
  • mice The opinion was modeled on mice. Skopylamin was administered as a dietary supplement (2.5 mg / kg) for 30 minutes before training. Extinction of memory evaluated the general method of passive avoidance in two- The storage or violation of the memory was evaluated at a constant time in the light (safe) if you ignore the violation of the data by ignoring Exodus entered.
  • Table 6 provides data on anti-amnesty * - 10 when the drug acts upon introducing it into the model of ammunition
  • Table 7 presents data on improvement due to the influence of the memory partition, the outdated and the old
  • Hexidol 50 mg / kg per day, inside 60 days
  • P ⁇ i is ⁇ lz ⁇ vanii me ⁇ sid ⁇ la as ine ⁇ tsy ⁇ i ⁇ u ⁇ s ⁇ v ⁇ y ⁇ e ⁇ a ⁇ ii (b ⁇ lee 30 days) nablgodae ⁇ sya
  • Disruptive and troubling drugs and tablets may be amenable to poor treatment, and
  • asthma type and other diseases associated with significant changes in the body’s disease and the implications are: a medical history of the disease, diabetes,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La substance neurotrope et sédative de l'invention contient du mexidol ainsi qu'un excipient, elle se présente sous la forme d'un comprimé présentant une âme contenant 16,7 à 41,6 % en poids de mexidol ainsi que des agents auxiliaires et un enrobage en polymère. Les agents auxiliaires se trouvant dans l'âme comprennent du kaolin (16,7 à 33,3 %), de l'amidon de pomme de terre (16,7 à 33,3 %), du stéarate de calcium (0,3 à 0,5 %), de l'acide stéarique (0,3 à 0,5 %), du talc (0,5 à 1,00 %), ainsi que de la méthylcellulose (25,0 à 50,0 %). Le procédé proposé d'obtention de cette substance neurotrope et sédative sous la forme d'un comprimé enrobé consiste à mélanger du mexidol, de l'amidon et du kaolin ensemble et à ajouter une solution de méthylcellulose, à granule, à sécher et à réduire en poudre le mélange avec du stéarate de calcium et de l'acide stéarique, à le comprimer afin de former des comprimés puis à le traiter avec une solution de méthylcellulose dans de l'alcool, du dioxide de titane et de la serge 80.
PCT/RU1995/000155 1994-07-15 1995-07-14 Agent neurotrope et sedatif et son procede d'obtention WO1996002238A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU94026856/14A RU2065299C1 (ru) 1994-07-15 1994-07-15 Ноотропное и транквилизирующее средство
RU94026856 1994-07-15

Publications (1)

Publication Number Publication Date
WO1996002238A1 true WO1996002238A1 (fr) 1996-02-01

Family

ID=20158556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1995/000155 WO1996002238A1 (fr) 1994-07-15 1995-07-14 Agent neurotrope et sedatif et son procede d'obtention

Country Status (2)

Country Link
RU (1) RU2065299C1 (fr)
WO (1) WO1996002238A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241310A2 (fr) 2009-04-17 2010-10-20 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations à libération modifiée d'émoxypine
EP2248516A1 (fr) * 2009-05-06 2010-11-10 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques d'emoxypine à désintégration orale
RU2798106C1 (ru) * 2021-12-27 2023-06-15 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая этилметилгидроксипиридина сукцинат

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2613019C1 (ru) * 2010-04-07 2017-03-14 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Фармацевтическая композиция для парентерального введения 2-этил-6-метил-3-гидроксипиридина сукцината и способ получения этой композиции
RU2445091C1 (ru) * 2010-11-09 2012-03-20 Алексей Сергеевич Гумилевский Фармацевтическая композиция в виде твердой лекарственной формы и способ ее получения
RU2444359C1 (ru) * 2010-12-06 2012-03-10 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Фармацевтическая композиция с 2-этил-6-метил-3-гидроксипиридина сукцината для перорального применения и способ ее получения
RU2664453C1 (ru) * 2017-11-24 2018-08-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Производное 3-гидроксипиридина с анксиолитической и ноотропной активностью
WO2019117820A1 (fr) 2017-12-14 2019-06-20 Madmit Trade, A. S. L-énantiomère du 2-éthyl-6-méthyl-3-hydroxypyridinium l-hydroxybutandioate à activités cérébroprotectrice, hépatoprotectrice, régulatrice des lipides, anti-ischémique et neurotrope
RU2668966C1 (ru) * 2018-01-25 2018-10-05 "Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ" (АО "ВНЦ БАВ") Комплексные соли ацексамовой кислоты, стимулирующие регенерацию костной ткани, ускоряющие процессы репаративного остеогенеза, стимулирующие минерализацию костной ткани при остеопорозе

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567250A1 (fr) * 1992-04-10 1993-10-27 R.J. Reynolds Tobacco Company Traitement de maladies neurodégénératives
EP0570294A1 (fr) * 1992-05-13 1993-11-18 Yale University Dérivés de 2-formylpyridine thiosemicarbazone, leur préparation et leur utilisation comme agents antitumoraux
US5352684A (en) * 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352684A (en) * 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments
EP0567250A1 (fr) * 1992-04-10 1993-10-27 R.J. Reynolds Tobacco Company Traitement de maladies neurodégénératives
EP0570294A1 (fr) * 1992-05-13 1993-11-18 Yale University Dérivés de 2-formylpyridine thiosemicarbazone, leur préparation et leur utilisation comme agents antitumoraux

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241310A2 (fr) 2009-04-17 2010-10-20 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations à libération modifiée d'émoxypine
TR200904159A1 (tr) * 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Değiştirilmiş salım sağlayan emoksipin formülasyonları.
EP2241310A3 (fr) * 2009-04-17 2011-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations à libération modifiée d'émoxypine
EP2248516A1 (fr) * 2009-05-06 2010-11-10 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques d'emoxypine à désintégration orale
TR200903548A1 (tr) * 2009-05-06 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan emoksipin bileşimleri
RU2798106C1 (ru) * 2021-12-27 2023-06-15 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая этилметилгидроксипиридина сукцинат

Also Published As

Publication number Publication date
RU94026856A (ru) 1996-09-27
RU2065299C1 (ru) 1996-08-20

Similar Documents

Publication Publication Date Title
Szczypka et al. Feeding behavior in dopamine-deficient mice
Resende et al. Effects of sodium butyrate in animal models of mania and depression: implications as a new mood stabilizer
WO1996002238A1 (fr) Agent neurotrope et sedatif et son procede d'obtention
Li et al. Food reward depends on TLR4 activation in dopaminergic neurons
PL188153B1 (pl) Lek zawierający nośnik materiałowy zaopatrzony w informację o biologicznie aktywnej substancji
Caprioli et al. Environmental modulation of cocaine self-administration in the rat
Hamilton et al. Behavioral effects of nicotine withdrawal in adult male and female rats
Valzelli et al. Psychoactive drug effect on behavioural changes induced by prolonged socio-environmental deprivation in rats
Falls et al. Procedures that produce context-specific tolerance to morphine in rats also produce context-specific withdrawal.
Sackett et al. Choice behavior in rhesus monkeys: Effect of stimulation during the first month of life
WO1993013764A1 (fr) Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
France et al. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies.
CN109453169A (zh) 草乌甲素的用途
WO2001064228A1 (fr) Procede de production d'une substance biologiquement active a partir du serum sanguin
Rabin et al. Interactions between radiation and amphetamine in taste aversion learning and the role of the area postrema in amphetamine-induced conditioned taste aversions
Pascuan et al. Involvement of nitric oxide in improving stress-induced behavioural alteration by glatiramer acetate treatment in female BALB/c mice
DE et al. Chronic ethanol feeding induces oxidative stress in the rat retina: treatment with the antioxidant ebselen
US3428729A (en) Controlled release formulation
Nmaju et al. Long-term consumption of capsicum annum (chilli pepper) and capsaicin diets suppresses pain perception and improves social behaviour of CD-1 mice
CN117243957A (zh) 具有抗应激、抗焦虑和抗抑郁活性的药物及其基础上的组合物
Anger et al. Effects of oral and intramuscular carbaryl administrations on repeated chain acquisition in monkeys
CN108938516A (zh) 一种安全无毒的驱蚊止痒剂及其制备方法
CN115475162B (zh) 4-异丁基-2-吡咯烷酮在制备镇痛药物中的应用、一种镇痛药物
CN114652708B (zh) 一种治疗深部组织疼痛的组合物
Kabachna et al. MECHANISMS OF ANALEPTIC AND ANTIGIPOXIC EFFECTS OF HETEROSIDES-(DERIVATIVES FOR SULFUR AND NITROGEN CONTAINING HETEROCYCLES)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): DE FR IT NL

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase